With our GPCR collection of 550 non-sensory GPCRs (300 human receptors and 250 mouse receptors) in native sequences, we provide functional assay for them in a single format, regardless of the subtypes of Gα proteins coupled. Click below for details or contact us for information about GPCRs of other animal species such as rats, rabbits, dogs, and macaque monkeys.
Filters Sort results
Reset Apply
Species | Receptor | Family | Assays | |
|---|---|---|---|---|
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: serotonin EC50: 13 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ Cardiology ⋅ à la carte |  Reference agonist: serotonin EC50: 4.0 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: serotonin EC50: 2.7 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: serotonin EC50: 3.2 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: serotonin EC50: 3.3 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Respiratory ⋅ à la carte |  Reference agonist: serotonin EC50: 1.9 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Cardiology ⋅ Respiratory ⋅ à la carte |  Reference agonist: serotonin EC50: 2.5 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: serotonin EC50: 1.7 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Cardiology ⋅ à la carte |  Reference agonist: serotonin EC50: 26 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ à la carte |  Reference agonist: serotonin EC50: 85 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ à la carte |  Reference agonist: serotonin EC50: 8.6 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: serotonin EC50: 1.8 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: carbachol EC50: 310 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: carbachol EC50: 110 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: carbachol EC50: 31 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: carbachol EC50: 47 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ à la carte |  Reference agonist: carbachol EC50: 5.9 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Neurology ⋅ Cardiology ⋅ Respiratory ⋅ à la carte |  Reference agonist: NECA EC50: 4.8 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Psychiatry ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: NECA EC50: 11 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Immunology/Infection ⋅ à la carte |  Reference agonist: NECA EC50: 19 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: NECA EC50: 1.6 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: L‐phenylephrine EC50: 18 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Neurology ⋅ Cardiology ⋅ à la carte |  Reference agonist: L‐phenylephrine EC50: 28 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: L‐phenylephrine EC50: 67 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ Cardiology ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: noradrenaline EC50: 71 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Psychiatry ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: noradrenaline EC50: 33 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Cardiology ⋅ à la carte |  Reference agonist: noradrenaline EC50: 89 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Cardiology ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: isoproterenol EC50: 22 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: isoproterenol EC50: 26 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Endocrinology/Metabolism ⋅ Cardiology ⋅ à la carte |  Reference agonist: isoproterenol EC50: 47 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: angiotensin ⅠⅠ EC50: 920 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Cardiology ⋅ à la carte |  Reference agonist: apelin‐13 EC50: 8.1 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: TGR5 agonist EC50: 350 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Respiratory ⋅ Dermatology ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: bombesin EC50: 2.4 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Psychiatry ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: GRP EC50: 1.3 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Dermatology ⋅ à la carte |  Reference agonist: NMB EC50: 590 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: calcitonin EC50: 2.7 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: CGRP EC50: 1.0 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: cinacalcet EC50: 140 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: Δ9‐THC EC50: 4.1 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ à la carte |  Reference agonist: Δ9‐THC EC50: 11 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: LPI EC50: 1.2 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: N‐oleoylethanolamine EC50: 6.3 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: chemerin EC50: 15 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: CCL3 EC50: 250 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CCL2 EC50: 1.3 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ à la carte |  Reference agonist: CCL22 EC50: 20 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CCL4 EC50: 7.1 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CCL20 EC50: 3.8 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Neurology ⋅ Ophthalmology ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: CCL21 EC50: 15 nM |
Contact Us
Send us a message via the form below or write to us at [email protected].
Ordering Process
Service flow chart
Request a quotation
We hear about the study outline and propose experiments. A non-disclosure agreement is optional.
STEP
1
Place an order
You place an order, ship your compounds to our lab, and pay the fee via bank transfer or by credit card.
STEP
2
Wait
The turnaround time can be as short as two weeks, depending on the study scale and design and the backlog of orders.
STEP
3
Receive the report
You receive the study report in PDF.
STEP
4